Drug intelligence / Profile preview

GM400

Development stage: Preclinical
Lead developer: GlycoMantra
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GM400 is an investigational Chimeric Antigen Receptor T-cell (CAR-T) therapy being developed by GlycoMantra for the treatment of kidney cancer. As a cell-based immunotherapy, it involves the genetic engineering of T cells to express a chimeric receptor that enables the immune system to recognize and eliminate malignant cells within the kidney. While GlycoMantra's broader research platform focuses on the role of galectins and glycans in the tumor microenvironment, the specific antigen target for the GM400 construct has not been publicly disclosed in early pipeline documentation.

Other names: GM400 CAR-T cell therapyGM-400 CAR-T cell therapyGM 400 CAR-T cell therapy

Targets

LGALS3 (Galectin-3)

Beyond the preview

Go deeper on GM400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM400.

Explore the full profile